WallStSmart

Canopy Growth Corp (CGC)vsHaleon plc (HLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Haleon plc generates 3862% more annual revenue ($11.03B vs $278.39M). HLN leads profitability with a 15.1% profit margin vs -117.3%. HLN earns a higher WallStSmart Score of 58/100 (C).

CGC

Avoid

30

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 5.0

HLN

Buy

58

out of 100

Grade: C

Growth: 5.3Profit: 7.0Value: 10.0Quality: 6.5
Piotroski: 5/9Altman Z: 2.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CGC.

HLNUndervalued (+51.3%)

Margin of Safety

+51.3%

Fair Value

$22.93

Current Price

$9.74

$13.19 discount

UndervaluedFair: $22.93Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CGC1 strengths · Avg: 10.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

HLN3 strengths · Avg: 8.7/10
EPS GrowthGrowth
92.0%10/10

Earnings expanding 92.0% YoY

Operating MarginProfitability
23.2%8/10

Strong operational efficiency at 23.2%

Free Cash FlowQuality
$1.26B8/10

Generating 1.3B in free cash flow

Areas to Watch

CGC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$424.29M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-48.5%2/10

ROE of -48.5% — below average capital efficiency

Revenue GrowthGrowth
-0.3%2/10

Revenue declined 0.3%

HLN2 concerns · Avg: 4.0/10
PEG RatioValuation
2.354/10

Expensive relative to growth rate

Revenue GrowthGrowth
0.6%4/10

0.6% revenue growth

Comparative Analysis Report

WallStSmart Research

Bull Case : CGC

The strongest argument for CGC centers on Price/Book.

Bull Case : HLN

The strongest argument for HLN centers on EPS Growth, Operating Margin, Free Cash Flow. Profitability is solid with margins at 15.1% and operating margin at 23.2%.

Bear Case : CGC

The primary concerns for CGC are EPS Growth, Market Cap, Return on Equity.

Bear Case : HLN

The primary concerns for HLN are PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

CGC profiles as a turnaround stock while HLN is a value play — different risk/reward profiles.

CGC carries more volatility with a beta of 2.34 — expect wider price swings.

HLN is growing revenue faster at 0.6% — sustainability is the question.

HLN generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

HLN scores higher overall (58/100 vs 30/100), backed by strong 15.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Canopy Growth Corp

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Canopy Growth Corporation is engaged in the production, distribution and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. The company is headquartered in Smiths Falls, Canada.

Haleon plc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Haleon plc (HLN) is a leading global consumer health company focused on delivering innovative health solutions across critical segments including oral care, pain relief, respiratory health, and dietary supplements. Formed from the spin-off of GlaxoSmithKline, Haleon boasts a strong portfolio of well-established brands, such as Sensodyne, Panadol, and Voltaren, solidifying its presence in the lucrative consumer health market. With a commitment to sustainability and consumer-driven innovation, the company is well-positioned to enhance health outcomes on a global scale while driving growth and delivering shareholder value through strategic investments and product advancements.

Visit Website →

Want to dig deeper into these stocks?